Nurse Practitioner Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Meghan McGrath

Nurse Practitioner, Family Great Falls, MT Nurse Practitioner

NPI 1326753807 CMS profile 11613058

1117 29Th St S, Great Falls, MT 59405

Open in the dashboard

General payments

$1,300

69 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Meghan McGrath of Great Falls, MT is reported in the CMS Open Payments database as having received $1,300 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,119 63
2024 General $181 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meghan McGrath
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Meghan McGrath were reported at $1,119. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Meghan McGrath Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $0 $141 $44–$430 $149
2023 $0 $154 $49–$476 $160
2024 $181 $165 $51–$504 $164
2025 $1,119 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. Incyte Corporation $157 4 payments
  2. Merck Sharp & Dohme Corporation $146 9 payments
  3. Pfizer Inc. $126 9 payments
  4. Celltrion USA Inc. $61 1 payment
  5. AbbVie, Inc. $56 3 payments
  6. Daiichi Sankyo Inc. $54 3 payments
  7. Sumitomo Pharma America, Inc. $52 3 payments
  8. AstraZeneca Pharmaceuticals LP $49 3 payments
  9. Aveo Pharmaceuticals, Inc. $46 3 payments
  10. Genzyme Corporation $40 2 payments
  11. Other $512 29 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $1,200 68 payments
  2. Education $100 1 payment
Products named General payments · program years 2024–2025
  1. KEYTRUDA $146 9 payments
  2. VEGZELMA $61 1 payment
  3. KEYTRUDA QLEX $60 3 payments
  4. JAKAFI $57 3 payments
  5. WELIREG $52 3 payments
  6. FOTIVDA $46 3 payments
  7. XTANDI $44 3 payments
  8. ORGOVYX $44 3 payments
  9. TALZENNA $44 3 payments
  10. TUKYSA $42 3 payments
  11. Other $1,052 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$1,168

Medicare's payments for the services billed

Medicare patients

12

Average age 64

Services billed

17

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
COPD 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ORGOVYX
  • Sumitomo Pharma America, Inc. $18
$18 — —
JAKAFI
  • Incyte Corporation $18
$18 — —
Orserdu
  • Stemline Therapeutics Inc. $15
$15 — —
LIBTAYO
  • Regeneron Healthcare Solutions, Inc. $13
$13 — —
Tecentriq Hybreza
  • Genentech USA, Inc. $6
$6 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Montana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record